摘要
目的:探究川芎嗪对类风湿性关节炎患者外周血IL-17、Foxp3的影响。方法:选取我院风湿科收治的类风湿性关节炎住院患者共60例,随机分为对照组30例,给予甲氨喋吟片与乐松片治疗,实验组30例,在对照组的基础上给予盐酸川芎嗪注射液,连续14 d。治疗期间观察患者有无不良反应,注意饮食,忌烟酒。治疗结束后,RT-PCR检测外周血RORTt、Foxp3 m RNA的表达;免疫组化检测外周血IL-17、Foxp3水平。结果:与治疗前相比,治疗后两组患者的RORTt水平明显降低,Foxp3水平明显增高,RORTt/Foxp3比值明显减小,治疗后,与对照组相比,RORTt、RORTt/Foxp3比值较低,Foxp3水平较高(P<0.05);与治疗前相比,治疗后两组患者的IL-17水平降低,Foxp3水平均升高(P<0.05),与对照组相比,上述指标改善更为明显(P<0.05)。结论:川芎嗪对类风湿性关节炎明显下调外周血RORTt水平,降低IL-17,升高Foxp3水平,提高患者免疫功能,从而减轻炎症反应,改善患者临床症状及不良预后,临床值得推广应用。
Objective： To investigate the effect of of the Peripheral Blood IL-17 and Foxp3 in rheumatoid arthritis patients by ligustrazine. Methods： 60 cases with rheumatoid arthritis were selected and randomly divided into two groups according to clinical medication guide, 30 cases each. The patients in control group were treated with methotrexate tablets, and the patients in experiment group were treated with ligustrazine hydrochloride injection based on control group for 14 days. After the treatment, the expression of peripheral blood RORTt and Foxp3 m RNA was detected by RT-PCR; and the level of IL-17 and Foxp3 in peripheral blood was detected by immunohistochemistry. Results： After treatment, RORTt, Foxp3 and RORTt/Foxp3 ratio level were all improved in two groups with significant difference compared with before treatment（P〈0.05）; and the change was more obviously in the experiment group compared with control group（P〈0.05）; after treatment, with the level of IL-17 was lower and Foxp3 was higher in two groups with statistically significant differences（P〈0.05）, and compared with the control group, the improvement of the indexes were more obvious in the experiment group with significant difference（P〈0.05）. Conclusions： Ligustrazine can reduce RORTt and IL-17 level and increase the Foxp3 level and improve the immunity function of patients with rheumatoid arthritis, so as to reduce inflammation and improve the clinical symptoms and prognosis.
出处
《现代生物医学进展》
CAS
2016年第17期3354-3358,3328,共6页
Progress in Modern Biomedicine
基金
陕西省自然科学基金项目(BK2010357)
